3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
50
Phase 1
30
Phase 3
20
Phase 1/2
17
Phase 2/3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
12
Carcinoma, Non-Small-Cell Lung
8
Ovarian Neoplasms
6
Fallopian Tube Neoplasms
5
Lung Neoplasms
4
Stomach Neoplasms
3
Esophageal Squamous Cell Carcinoma
3
Esophageal Neoplasms
3
Endometrial Neoplasms
3
Carcinoma, Ovarian Epithelial
3
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Inflammatory Breast Neoplasms
2
Head and Neck Neoplasms
2
Carcinoma, Ductal, Breast
2
Adenocarcinoma Of Esophagus
2
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
The Neoadjuvant Therapy
1
Testicular Neoplasms
1
Testicular Germ Cell Tumor
1
Teratoma
1
Stage IIIB or IV Non-Small Cell Lung Cancer
1
Seminoma
1
Recurrence
1
Primary Malignant Neoplasm of Ovary
1
Peripheral Nervous System Diseases
1
Pancreatic Neoplasms
1
Neoplasms, Cystic, Mucinous, and Serous
1
Neoplasm Metastasis
1
Interventions
Gemcitabine
5
Capecitabine
4
pembrolizumab
3
Fluorouracil
3
Cisplatin
3
vinflunine
2
enzalutamide
2
cabazitaxel
2
abiraterone
2
Ipilimumab
2
Haloperidol
2
Androgen Antagonists
2
vedolizumab
1
trifluridine tipiracil drug combination
1
relugolix
1
racemetyrosine
1
nimotuzumab
1
nilutamide
1
lanreotide
1
histrelin
1
futibatinib
1
exemestane
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
bicalutamide
1
beta-Glucans
1
auricularum
1
atezolizumab
1
apatinib
1
apalutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Neoplasm Metastasis
×
Paclitaxel
×
Clear all
NCT01572727
2017-03-09
BELLE-4
Novartis
Phase 2/3
Completed
416 enrolled
11 charts